n n n ‘. concat(e. i18n. t(“search. voice. recognition_retry”),’n
Anjalee Khemlani, fitness journalist at Yahoo Finance, summarizes her interview with Moderna CEO Stéphane Bancel about the company’s $1 billion investment in mRNA production facilities in China.
“There’s a very strong agreement at the highest point between the U. S. government and the Chinese government that they need to collaborate on physical care, on climate and on food insecurity,” Bancel said. “We have all these respiratory, latent vaccines. ” We need as many other people in the world as possible to benefit from these products to avoid disease. “
For more information and the latest market actions, click here to watch this full episode of Yahoo Finance Live.
Moderna (MRNA) is moving 3 of its vaccines to 3 trials as the pharmaceutical giant hopes to expand its product portfolio beyond its COVID-19 vaccine, whose sales fell 43% year-over-year in 2023.
Anjalee Khemlani, fitness journalist at Yahoo Finance, summarizes her interview with Moderna CEO Stéphane Bancel about the company’s $1 billion investment in mRNA production facilities in China.
“There is a very strong agreement at the highest point between the U. S. government and the Chinese government on the willingness to collaborate on physical care, climate and food insecurity,” Bancel said. “We have all these respiratory, latent vaccines. ” We need as many other people in the world as possible to benefit from these products to avoid disease. “
For more information and the latest market actions, click here to watch this full episode of Yahoo Finance Live.
Editor’s Note: This article is written by Luke Carberry Mogan.
[AUDIO LOGO]
– Moderna is looking to recover from the COVID crisis, with the pharmaceutical company announcing advancements in its Moderna and mRNA vaccine portfolio instead of disclosing positive results from the Phase III trial for its next-generation COVID 19 vaccine. Yahoo Finance fitness journalist Anjalee Khemlani is here with us. Anjalee, what did you learn about this interview?
ANJALEE KHEMLANI: Well, it’s appealing because Moderna is just the COVID 19 company. But it’s entering a year of prospective growth, pulling the company out of the post-pandemic lull we experienced last year. And that’s why CEO Stéphane Bancel announced those new initiatives, the new vaccine is updated today on its annual Vaccine Day.
The company will also bolster its global presence with a $1 billion investment in mRNA production in China. And we know it’s a vital area that large-cap companies can participate in. But recent congressional efforts to ban Chinese biotech companies have created some tension in the industry.
As it turns out, this tension doesn’t affect Bancel. He previously told Yahoo Finance that he wasn’t worried. Here’s what I had to say.
STEPHANE BANCEL: I think there’s a very strong agreement at the highest point between the U. S. government and the Chinese government on the willingness to work together on physical care, climate, and food insecurity. Here are the 3 topics they need to collaborate on at the highest point. We need to help other people and protect them. That’s why the company was created. With all those respiratory and latent vaccines, we need as many other people in the world as possible to benefit from those products to avoid disease.
ANJALEE KHEMLANI: So, there are potentially exceptions for the company. Meanwhile, Moderna is also working to ramp up its research and development. This is a domain that you want to commit to continuing this growth. He recently won a $750 million injection from Blackstone Life Sciences for his flu program. And that’s the first thing. Moderna is still running before turning to COVID.
The company also has several applicants in the pipeline who would bring the off-season activity to life despite last year’s production cuts. One of their biggest partners was Catalent, and now they are acquired through Novo Nordisk. So I asked Bancel if I was going to replace anything or the company. Here’s what he said.
STEPHANE BANCEL: The acquisition of Catalent through Novo Nordisk did not replace anything for us because we were really leaving Catalent, the Indiana site, which is the one considered part of our 24 program. What is vital is that the latent virus does not the season occurs.
So if you think about Moderna, today our production is not as effective as it should be because we’re producing COVID for the season. But let’s say in the first quarter, we didn’t make a lot of products. We manufacture clinical trial batches for all clinical trial studies, but we do not manufacture advertising products in-house.
So all those latent viruses as they’re released, we can create them in the first trimester or second before a season and have much better use, and our product load will be particularly as we launch those products. So we don’t want subirlos. fabricación. No we want to raise CapEx, so it’s wonderful news in terms of power and backtracking on the equity that we can create.
ANJALEE KHEMLANI: It turns out it worked at least for the company. But we’ll have to see how those vaccines progress through the process and wait for them to reach the market.